Case report A 9 month old girl with retarded growth and development and intractable epilepsy was admitted to the National Kure Hospital because of partial seizures and petechiae. Her neonatal history was uneventful and her weight at birth was 2900 g. She was well until she was 1 month old, when she had brief generalised seizures associated with nausea. She later had partial seizures with facial automatism. These seizures did not respond to conventional doses of several antiepileptic drugs, including valproic acid. As she continued to have partial seizures, the dose of valproic acid was progressively increased to 64 mg/kg/day. She had thrombocytopenia without haemorrhagic manifestations one month after starting the high dose valproic acid treatment.
The reported adverse haematological effects of valproic acid treatment include thrombocytopenia and platelet dysfunction. Less common haematological toxicities included leucopenia and bone marrow failure.' 2 The pathophysiology of bone marrow failure remain unknown. It has been postulated that valproic acid has a possible direct toxic effect on bone marrow progenitor cells. 3 We report here the case of a girl who had severe erythrocyte hypoplasia and thrombocytopenia during treatment with valproic acid. The aim of our study was to elucidate the pathophysiology of bone marrow suppression in this patient by determining the toxicity of valproic acid on the in vitro colony growth of haematopoietic progenitors.
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Results
To assess a possible direct toxic effect of valproic acid on bone marrow progenitor cells, we studied CFU-GM and CFU-E in the presence of three doses of valproic acid (50, 100, and 200 mg/l) (table). In CFU-GM at valproic acid concentrations less than 100 mg/l, inhibition was not observed compared with the control culture without valproic acid. At a high concentration of valproic acid (200 mg/l), similar to the serum concentration of our patient on admission, there was marked inhibition of CFU-GM growth. The colony growth was 31% (64 colonies) and 50% (20 colonies) of that seen in control cultures without valproic acid in a normal control and our patient respectively.
In CFU-E, at concentrations greater than 100 mg/l, valproic acid markedly inhibited CFU-E growth in the normal control and the patient. There was only one colony (25% of growth) in the cultures from the patient at a valproic acid concentration of 100 mg/l. No colony growth was detected at a valproic acid concentration of 200 mg/l (table). These inhibitions were of the same order of magnitude in the two cell sources. Valproic acid was more toxic to CFU-E than to CFU-GM, however.
Discussion
In our patient, the peripheral blood and bone marrow findings indicated severe anaemia due to erythroid hypoplasia, amegakaryocytic thrombocytopenia, and the Pelger-Huet anomaly without neutropenia during valproic acid treatment. Valproic acid affected all three bone marrow cell lines. These cytopenias recovered after the discontinuation of valproic acid and concomitant supportive treatments and seemed to be due to valproic acid. These haematological abnormalities in bone marrow cells, which have been reported on only two previous occasions,' 2 seem to be rare complications of treatment with valproic acid. Smith and Boots postulated that the bone marrow suppression was most likely to be related to valproic acid and that valproic acid induced bone marrow suppression may explain the discrepancy between commonly reported decreases in platelet count and the relatively low incidence of platelet autoantibodies. 1 Watts et al quantified CFU-GM and CFU-E in the presence of increasing doses of valproic acid to evaluate a possible direct toxic effect of valproic acid.3 They observed consistent dose dependent inhibition only in normal adult bone marrow. They did not determine whether patients with haematological abnormalities are more sensitive than normal controls to valproic acid toxicity. In our study bone marrow culture studies showed that valproic acid suppressed CFU-GM and CFU-E in vitro at the high concentration of 200 mg/l, and that the degree of suppression was the same in the normal control and the patient. Therefore, the bone marrow suppression was probably the result of direct suppression by valproic acid, and our patient was not easily susceptible to bone marrow suppression by valproic acid. In the light of toxic effects of valproic acid on haematopoietic cells, neutropenia and anaemia might be common, but these cytopenias are indeed rare complications. The reason why these cytopenias do not develop remains unclear. Perhaps there are other factors involved.
Studies on the rational treatment of refractory epilepsy have reported the efficacy of treatment with high dose valproic acid. Thrombocytopenia and hypofibrinogenaemia were often seen with high dose valproic acid, but not abnormalities of the erythroid or myeloid series.6 In our studies, valproic acid did not inhibit bone marrow function at a concentration less than 100 mg/l. There was marked in vitro suppression of bone marrow at the high valproic acid concentration of 200 mg/l. We emphasise the need for close haematological monitoring of patients receiving high dose valproic acid treatment.
